Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from OptiBiotix Health ( (GB:OPTI) ) is now available.
OptiBiotix Health plc announced the publication of a new study on its product SlimBiome® in the European Journal of Nutrition. The study, led by Professor Adele Costabile, found that a single dose of SlimBiome® significantly reduced insulin levels, hunger, and the desire to eat while increasing fullness, highlighting its potential as a non-pharmaceutical weight management solution. These findings support health claims for appetite regulation and differentiate SlimBiome® from other market products. The study’s results align with consumer feedback and previous studies, indicating SlimBiome®’s effectiveness in sustainable weight management. This development positions OptiBiotix favorably in the evolving weight management market, which is increasingly favoring science-backed products over traditional methods.
More about OptiBiotix Health
OptiBiotix Health plc, founded in March 2012, is a life sciences company focused on developing compounds that modify the human microbiome to prevent and manage diseases and promote wellness. The company has an extensive R&D program and collaborates with international food and healthcare supplement companies to incorporate its microbiome modulators into various products. OptiBiotix is also developing its own range of consumer supplements and health products, focusing on obesity, cardiovascular health, and diabetes.
Average Trading Volume: 400,956
Technical Sentiment Signal: Strong Sell
Current Market Cap: £13.17M
Find detailed analytics on OPTI stock on TipRanks’ Stock Analysis page.